These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 25450029)
1. A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. Zibelman M; Barth P; Handorf E; Smaldone MC; Kutikov A; Uzzo RG; Bilusic M; Plimack ER; Wong YN; Geynisman DM Clin Genitourin Cancer; 2015 Apr; 13(2):142-9. PubMed ID: 25450029 [TBL] [Abstract][Full Text] [Related]
2. Novel immunotherapeutic strategies in development for renal cell carcinoma. Inman BA; Harrison MR; George DJ Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331 [TBL] [Abstract][Full Text] [Related]
3. Pazopanib for the treatment of metastatic renal cell carcinoma. Pick AM; Nystrom KK Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567 [TBL] [Abstract][Full Text] [Related]
4. Integration of surgery and systemic therapy for renal cell carcinoma. Kenney PA; Wood CG Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764 [TBL] [Abstract][Full Text] [Related]
5. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008 [TBL] [Abstract][Full Text] [Related]
6. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275 [TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma in children: experience of a single center. Varan A; Akyuz C; Sari N; Buyukpamukçu N; Cağlar M; Buyukpamukçu M Nephron Clin Pract; 2007; 105(2):c58-61. PubMed ID: 17135769 [TBL] [Abstract][Full Text] [Related]
8. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050 [TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Neuzillet Y; Tillou X; Mathieu R; Long JA; Gigante M; Paparel P; Poissonnier L; Baumert H; Escudier B; Lang H; Rioux-Leclercq N; Bigot P; Bernhard JC; Albiges L; Bastien L; Petit J; Saint F; Bruyere F; Boutin JM; Brichart N; Karam G; Branchereau J; Ferriere JM; Wallerand H; Barbet S; Elkentaoui H; Hubert J; Feuillu B; Theveniaud PE; Villers A; Zini L; Descazeaux A; Roupret M; Barrou B; Fehri K; Lebret T; Tostain J; Terrier JE; Terrier N; Martin L; Dugardin F; Galliot I; Staerman F; Azemar MD; Irani J; Tisserand B; Timsit MO; Sallusto F; Rischmann P; Guy L; Valeri A; Deruelle C; Azzouzi AR; Chautard D; Mejean A; Salomon L; Rigaud J; Pfister C; Soulié M; Kleinclauss F; Badet L; Patard JJ; ; Eur Urol; 2011 Aug; 60(2):366-73. PubMed ID: 21377780 [TBL] [Abstract][Full Text] [Related]
10. Metastatic renal cell carcinoma: many treatment options, one patient. Rini BI J Clin Oncol; 2009 Jul; 27(19):3225-34. PubMed ID: 19470934 [TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
13. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485 [TBL] [Abstract][Full Text] [Related]
14. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919 [TBL] [Abstract][Full Text] [Related]
16. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ; BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Sun M; Shariat SF; Cheng C; Ficarra V; Murai M; Oudard S; Pantuck AJ; Zigeuner R; Karakiewicz PI Eur Urol; 2011 Oct; 60(4):644-61. PubMed ID: 21741163 [TBL] [Abstract][Full Text] [Related]
18. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034 [TBL] [Abstract][Full Text] [Related]
19. Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. Rizzo A; Mollica V; Dall'Olio FG; Ricci AD; Maggio I; Marchetti A; Rosellini M; Santoni M; Ardizzoni A; Massari F Future Oncol; 2021 Jul; 17(20):2671-2681. PubMed ID: 33880963 [TBL] [Abstract][Full Text] [Related]
20. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. May M; Brookman-May S; Hoschke B; Gilfrich C; Kendel F; Baxmann S; Wittke S; Kiessig ST; Miller K; Johannsen M Cancer Immunol Immunother; 2010 May; 59(5):687-95. PubMed ID: 19876628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]